An extracellular vesicular mutant KRAS‐associated protein complex promotes lung inflammation and tumor growth
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Extracellular Vesicles"
DOI: 10.1002/jev2.12307
Abstract: Abstract Extracellular vesicles (EVs) contain more than 100 proteins. Whether there are EVs proteins that act as an ‘organiser’ of protein networks to generate a new or different biological effect from that identified in EV‐producing… read more here.
Keywords: protein complex; inflammation; mutant kras; lung inflammation ... See more keywords
Fusobacterium nucleatum promotes tumor progression in KRAS p.G12D-mutant colorectal cancer by binding to DHX15
Sign Up to like & getrecommendations! Published in 2024 at "Nature Communications"
DOI: 10.1038/s41467-024-45572-w
Abstract: Fusobacterium nucleatum (F. nucleatum) promotes intestinal tumor growth and its relative abundance varies greatly among patients with CRC, suggesting the presence of unknown, individual-specific effectors in F. nucleatum-dependent carcinogenesis. Here, we identify that F. nucleatum… read more here.
Keywords: crc; g12d mutant; nucleatum promotes; fusobacterium nucleatum ... See more keywords
Abstract 5770: Inhibition of KRAS G12D mutant with small molecules
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-5770
Abstract: Background: RAS mutations are occurring at a high rate in colorectal cancer, lung cancer, and pancreatic cancer. RAS is family of small GTPase proteins with important roles in cell growth, differentiation, proliferation, and survival. There… read more here.
Keywords: cancer; q2a compound; g12d mutant; kras g12d ... See more keywords
Abstract 5900: INCB161734: A novel, potent, and orally bioavailable KRAS G12D selective inhibitor demonstrates antitumor activity in KRAS G12D mutant tumors
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-5900
Abstract: KRAS G12D (G12D) is one of the most frequent oncogenic driver mutations, and is especially common in pancreatic (PDAC) and colorectal (CRC) cancers. Patients with G12D-mutated disease experience poor treatment outcomes, representing a significant unmet… read more here.
Keywords: incb161734; orally bioavailable; g12d mutant; cell ... See more keywords
Abstract 6050: Targeting KRAS G12D mutant tumors with the PROTAC degrader RP03707
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-6050
Abstract: RAS oncogene mutations are prevalent in approximately 19% of cancer patients, with the most frequent alteration occurring in codon 12 of the KRAS gene, resulting in a variety of G12X oncoproteins. Recent advances in drug… read more here.
Keywords: g12d mutant; tumor; rp03707; targeting kras ... See more keywords
Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant—Novel Insights from Computer-Aided Drug Discovery
Sign Up to like & getrecommendations! Published in 2023 at "Current Issues in Molecular Biology"
DOI: 10.3390/cimb45030137
Abstract: The KRAS G12D mutation is very frequent in many cancers, such as pancreatic, colon and lung, and has remained undruggable for the past three decades, due to its smooth surface and lack of suitable pockets.… read more here.
Keywords: kras g12d; bioflavonoids potential; dietary bioflavonoids; g12d mutant ... See more keywords